Loading
A phase 3 trial of Irinotecan, Floxuridine, Leucovorin, Fluorouracil and Oxaliplatin in Colorectal cancer, run by Sun Yat-sen University, recorded as terminated on the registry.
FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM is a phase 3 interventional study registered as NCT03678428 by Sun Yat-sen University, with 92 participants recorded, started 2021-12-31 and due to reach its primary completion in 2022-10-31. Interventions recorded: Irinotecan, Oxaliplatin HAI, Floxuridine, Leucovorin, 5-FU, Oxaliplatin. Conditions recorded: Metastatic Colorectal Cancer, Liver Metastases.
Linked to the drug Floxuridine because the registry names it among its interventions and Colorectal cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Floxuridine, Irinotecan (and liposomal irinotecan), Leucovorin (folinic acid), Oxaliplatin and the tag pipeline.
Shares Floxuridine, Oxaliplatin, Colorectal cancer and the tag pipeline.
Shares Irinotecan (and liposomal irinotecan), Leucovorin (folinic acid), Fluorouracil (5-FU), Colorectal cancer and the tag pipeline.
Shares Leucovorin (folinic acid), Oxaliplatin, Fluorouracil (5-FU), Colorectal cancer and the tag pipeline.
Shares Irinotecan (and liposomal irinotecan), Leucovorin (folinic acid), Fluorouracil (5-FU), Colorectal cancer and the tag pipeline.
Shares Irinotecan (and liposomal irinotecan), Fluorouracil (5-FU), Colorectal cancer and the tag pipeline.
Shares Leucovorin (folinic acid), Fluorouracil (5-FU), Colorectal cancer and the tag pipeline.
Shares Leucovorin (folinic acid), Oxaliplatin and the tag pipeline.